JPMorgan Resumes Ratings on 14 Biotechs, Sets $515 Vertex and $420 Alnylam Targets
JPMorgan reinstated ratings and price targets on 14 large-cap biotech firms, projecting December 2026 targets including $515 for Vertex, $420 for Alnylam, $415 for BeOne and $180 for Insmed. Analysts highlighted sustained profitability at Vertex, Alnylam and BeOne, margin expansion, diversification moves at BioMarin and Moderna’s oncology push as catalysts.
1. Coverage Reinstatement and Sector Inflection
JPMorgan reinstated ratings and price targets for 14 large-cap biotechnology companies, characterizing the group as entering a critical inflection point as pipeline successes translate into profitable franchises.
2. Profitability Momentum and Diversification
Several firms including Vertex, Alnylam and BeOne have achieved sustained profitability while Insmed and Ionis are nearing that milestone; diversification efforts encompass Vertex’s renal disease expansion, BioMarin’s rare disease acquisitions and Moderna’s oncology mRNA applications.
3. Analyst Ratings and Price Targets
Analysts assigned Overweight ratings to Vertex, Alnylam, BeOne, United Therapeutics, Insmed, Ascendis, Jazz, Ionis, BioMarin and Mirum, Neutral to BioNTech, Incyte and Halozyme, and Underweight to Moderna, setting December 2026 targets such as $515 for Vertex, $420 for Alnylam, $415 for BeOne, $685 for United Therapeutics and $180 for Insmed.
4. Clinical Catalysts on the Horizon
Upcoming catalysts include cardiovascular outcomes trials for Ionis’s partnered therapies and pivotal renal readouts from Vertex, which could drive margin expansion and share-price momentum across the sector.